Form 10-Q/A
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 10-Q/A
Amendment No. 1
 
     
þ   Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Quarterly Period ended September 30, 2009
     
o   Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Transition Period from                             to                            
Commission File Number 001-33043
 
ImaRx Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
 
     
Delaware   86-0974730
(State or Other Jurisdiction of   (I.R.S. Employer
Incorporation or Organization)   Identification No.)
     
ImaRx Therapeutics, Inc.    
c/o Stoel Rives LLP    
201 S. Main Street, Suite 1100    
Salt Lake City, Utah   84111
(Address of Principal Executive Offices)   (Zip Code)
(801) 578-6962
(Registrant’s Telephone Number, Including Area Code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for at least the past 90 days. YES þ NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES o NO o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
             
Large accelerated Filer o   Accelerated Filer o   Non-accelerated filer o   Smaller reporting company þ
        (Do not check if a smaller reporting company)    
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES o NO þ
The number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date is as follows:
     
Class   Outstanding at December 29, 2009
Common Stock $0.0001 par value   11,665,733
 
 

 

 


 

EXPLANATORY NOTE
ImaRx Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 (the “Report”) for the sole purpose of amending Exhibit Nos. 31.1 and 31.2 to include the introductory language of paragraph 4 and the language of paragraph 4(b) of Item 601(b)(31) Regulation S-K  
Except as described above, no other changes are made to Report, and this Form 10-Q/A does not amend, update or change any other Item or the disclosures in the Report in any way. This Form 10-Q/A does not reflect events occurring after the filing of the Report or modify or update those disclosures, including any exhibits to the Report, affected by subsequent events.
Item 6. Exhibits.
Exhibits
                                 
                Incorporated by Reference
Exhibit       Filed       Exhibit        
No.   Exhibit Title   Herewith   Form   No.   File No.   Filing Date
       
 
                       
  31.1    
Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
  X                    
       
 
                       
  31.2    
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
  X                    
       
 
                       
  32    
Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Office
      10-Q     32     001-33043   November 16, 2009

 

2


 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10Q/A to be signed on its behalf by the undersigned, thereunto duly authorized.
         
  IMARX THERAPEUTICS, INC.
 
 
Date: December 29, 2009  By:   /s/ RICHARD LOVE    
    Richard Love,   
    Chairman of the Board
(Principal Executive Officer and Principal Financial Officer) 
 

 

3


 

EXHIBIT INDEX
Exhibit Index
                                 
                Incorporated by Reference
Exhibit       Filed       Exhibit        
No.   Exhibit Title   Herewith   Form   No.   File No.   Filing Date
       
 
                       
  31.1    
Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
  X                    
       
 
                       
  31.2    
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
  X                    
       
 
                       
  32    
Section 1350 Certification of Periodic Financial Report by the Chief Executive Officer and Principal Financial and Accounting Officer
      10-Q     32     001-33043   November 16, 2009

 

4